Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Disease Duration <10 and ≥10 Years: Analysis of Two Phase 3 Studies

Main Article Content

Benjamin Ehst
George Han
Scott Guenthner
Kimberly Eads
Abby Jacobson

Keywords

psoriasis, brodalumab

Abstract

Abstract not available.

References

1. Siliq [package insert]. Valeant Pharmaceuticals North America LLC; 2017.

2. Lebwohl et al. N Engl J Med. 2015;373:1318-1328.